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Abstract 9 
Modification of specific Ser and Thr residues of nucleocytoplasmic proteins with O-GlcNAc, catalyzed by O-10 
GlcNAc transferase (OGT), is an abundant post-translational event essential for proper animal development 11 
and dysregulated in various diseases. Due to the rapid concurrent removal by the single O-GlcNAcase 12 
(OGA), precise functional dissection of site-specific O-GlcNAc modification in vivo is currently not possible 13 
without affecting the entire O-GlcNAc proteome. Exploiting the fortuitous promiscuity of OGT, we show that 14 
S-GlcNAc is a hydrolytically stable and accurate structural mimic of O-GlcNAc that can be encoded in 15 
mammalian systems with CRISPR-Cas9 in an otherwise unperturbed O-GlcNAcome. Using this novel 16 
approach, we target an elusive Ser405 O-GlcNAc site on OGA, showing that this site-specific modification 17 
affects OGA stability.  18 
 3
Introduction 19 
Protein O-GlcNAcylation is a ubiquitous and dynamic nucleocytoplasmic post-translational modification of 20 
serines and threonines with O-linked β-N-acetylglucosamine (O-GlcNAc)1. Thousands of protein substrates 21 
are modified by O-GlcNAc transferase (OGT)2 while a single enzyme, O-GlcNAc hydrolase (OGA)3, 22 
removes the modification. Importantly, OGT is required for proper development in mice and fruit flies4,5. On 23 
the other hand, disruption of O-GlcNAc cycling on specific proteins is associated with cancer6, diabetes7, 24 
neurodegeneration8 and a recently described intellectual disability syndrome9. 25 
   Functional dissection of individual O-GlcNAc sites has so far relied on alanine mutagenesis or modulation 26 
of OGA or OGT activity through inhibition or knockdown. However, these approaches are confounded by 27 
undesirable effects on the entire O-GlcNAcome. Methods for introducing site-specific stoichiometric O-28 
GlcNAc modification are limited to in vitro chemical biology techniques such as expressed protein ligation. 29 
Yet, only a few O-GlcNAcylated proteins have been produced using this method, including tau and α-30 
synuclein10,11. Another in vitro method, relying on the chemical conversion of a cysteine (introduced by site-31 
directed mutagenesis) to dehydroalanine and subsequent reaction with a GlcNAc derivative, is limited to 32 
proteins that do not contain (many) native cysteine residues and is not stereo-specific12. Site-specific 33 
incorporation of O-GlcNAc in the context of a living biological system has not been achieved yet. 34 
   Given that the O-GlcNAc modification is prone to hydrolysis by OGA, site-specific O-GlcNAcylation in 35 
cells, even if achieved, would not be permanent. Interestingly, OGA itself belongs to a plethora of OGT 36 
substrates and the modification site (Ser405) is conserved among vertebrates (Fig. 1a)13,14. Previously, this 37 
O-GlcNAc modification was shown to be inducible by OGA inhibition, while being minimal at basal 38 
conditions15,16. However, studying this phenomenon presents a paradox – even if stoichiometric O-39 
GlcNAcylation of catalytically active OGA could be achieved, its own hydrolase activity would remove it. 40 
Therefore, the investigation of the regulatory functions of O-GlcNAc modification on OGA, and other OGT 41 
substrates, would require site-specific installation of an OGA-resistant functional mimic of O-GlcNAc. 42 
   A thio-linked GlcNAc (S-GlcNAc) has potential to resist OGA-mediated hydrolysis. It was initially shown 43 
that the pseudo-substrate peptide Ala-Cys-(S-GlcNAc)-Ala inhibits a highly active bacterial OGA orthologue 44 
from Clostridium perfringens (CpOGA) at low micromolar concentrations, implying that S-GlcNAc may be a 45 
hydrolytically stable mimic of O-GlcNAc in the context of a peptide backbone17. The non-hydrolysable S-46 
GlcNAc modification has been successfully applied as an O-GlcNAcylation mimic in vitro in the context of 47 
several recombinant proteins, such as casein kinase 2 (CK2), histone H2B, α-synuclein and tau18–21.      48 
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Therefore, S-GlcNAc, if site-specifically incorporated, presents an attractive candidate for studying the 49 
effects of permanent O-GlcNAcylation. Nonetheless, production of such S-GlcNAcylated proteins has thus 50 
far been limited to in vitro approaches. Here we establish a straightforward method for site-specific 51 
installation of S-GlcNAc mimic in vivo, compatible with CRISPR-Cas9 genome editing. We show that the O-52 
GlcNAc site on the O-GlcNAcase regulates its half-life, adding to the growing body of evidence that 53 
suggests a link between O-GlcNAcylation and protein stability. 54 
 55 
Results  56 
S-GlcNAc is a non-hydrolysable O-GlcNAc analogue 57 
   A prerequisite for the incorporation of S-GlcNAc as a stable O-GlcNAc mimic is resistance to the action of 58 
OGA. Although some studies support this17,20, we wondered whether S-GlcNAcylation would be resistant to 59 
OGA hydrolysis in the context of human OGA (hOGA). To investigate this, short synthetic peptides (bearing 60 
the S- or O-GlcNAc modification) derived from hOGA were subjected to treatment with CpOGA, a 61 
promiscuous, bacterial orthologue of the human enzyme with elevated activity17. Analysis of the products by 62 
MALDI-TOF mass spectrometry revealed loss of modification on the O-GlcNAcylated peptide after just 4 h 63 
of CpOGA treatment (Fig. 1b), whereas the S-GlcNAcylated peptide remained intact for at least 24 h (Fig. 64 
1b). 65 
   Next we asked whether the S-GlcNAc modification is an adequate structural mimic of the O-GlcNAc 66 
modification in the context of proteins that recognize the O-GlcNAc modification, such as OGA and recently 67 
discovered O-GlcNAc readers22. We employed a fluorescence polarimetry competition assay23 to compare 68 
the binding affinities of Ser-O-GlcNAc and Cys-S-GlcNAc in the context of a peptide, using a catalytically 69 
incompetent mutant of CpOGA (CpOGAD298N) as a model O-GlcNAc ‘’reader’’24. Encouragingly, 70 
CpOGAD298N did bind the hOGA S-GlcNAcylated peptide with a KD value in the μM range, albeit two orders 71 
of magnitude lower than the O-GlcNAcylated equivalent (Fig. 1c). These data suggest that S-GlcNAc will 72 
likely be recognized by a range of O-GlcNAc binding proteins, and is an adequate mimic of the O-GlcNAc 73 
modification. 74 
   Although Cys-S-GlcNAc is expected to most accurately mimic Ser-O-GlcNAc, we wondered whether Thr-75 
O-GlcNAc could also be replaced with a non-hydrolysable S-GlcNAc. To investigate this, we synthesized O- 76 
and S-GlcNAcylated peptides derived from the Thr72 O-GlcNAcylation site of α-synuclein11 and subjected 77 
them to treatment with active CpOGA. The latter completely removed the modification on Thr-O-GlcNAc 78 
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peptide after 24 h, while the Cys-S-GlcNAcylated counterpart remained stable (Extended Data Fig. 1a). 79 
Interestingly in a binding assay, the affinity of inactive CpOGA for Cys-S-GlcNAcylated peptide was just one 80 
order of magnitude weaker (Extended Data Fig. 1b). Thus, Cys-S-GlcNAc could potentially be used to 81 
mimic Thr-O-GlcNAc. 82 
   To further corroborate the structural mimicry, we investigated whether the conformation of Cys-S-GlcNAc 83 
is similar to Ser-O-GlcNAc in the context of a binding protein. We have previously reported crystal 84 
structures of O-GlcNAcylated peptides in complex with CpOGAD298N, including a complex with a peptide 85 
encompassing Ser405 of hOGA25.  We soaked CpOGAD298N crystals with the S-GlcNAcylated hOGA 86 
peptide and obtained synchrotron diffraction data (Table 1). Molecular replacement with the previously 87 
reported CpOGA structure revealed well-defined difference density covering the S-GlcNAc moiety and the 88 
peptide backbone (Fig. 1d). Further refinement resulted in a final model with R/Rfree = 0.19/0.23 (Table 1). 89 
Comparison of the positions and conformations of the O- and S-GlcNAcylated peptides reveals them to 90 
bind in a similar fashion (sugar atomic positional shifts < 0.3 Å, Fig. 1d) with conservation of the hydrogen 91 
bonds of the sugar moiety with Asp401, Tyr335, Asn298 and Asp297 (Fig. 1d). 92 
 93 
S-GlcNAc can be genetically incorporated in the context of O-GlcNAc sites 94 
   Having confirmed that S-GlcNAc appears to be a non-hydrolysable functional mimic of O-GlcNAc, we 95 
sought a straightforward approach for site-specific incorporation of this modification in vivo. Interestingly, 96 
the existence of S-GlcNAc on mammalian proteins was demonstrated recently26. Moreover, using an in vitro 97 
assay it was shown that cysteine residues in certain peptide sequences could be S-GlcNAcylated by 98 
OGT26. Inspired by this report, we hypothesized that OGT could modify cysteine residues in the context of 99 
O-GlcNAcylation sites in proteins, such as a well-characterized single O-GlcNAcylation site (Ser395) on the 100 
innate immunity signaling node TGF-β activated kinase binding protein 1 (TAB1)27. 101 
   To test whether S395C mutation on TAB1 would result in S-GlcNAcylation, the recombinant protein was 102 
incubated with OGT and UDP-GlcNAc followed by MS/MS analysis using Electron-Transfer/Higher-Energy 103 
Collision Dissociation (EThcD). In line with our hypothesis, cysteine-S-GlcNAcylation was unambiguously 104 
detected on TAB1S395C (Fig. 2a), confirming the reported S-GlcNAc transferase activity of OGT26. 105 
   We have previously generated a site-specific O-GlcNAc TAB1 Ser395 antibody (gTAB1)27 and used this 106 
on Cys395 S-GlcNAcylated TAB1 to further investigate structural mimicry. In a control experiment, in vitro 107 
OGT assay revealed a time-dependent increase of O-GlcNAcylation on wild type TAB1 using the gTAB1 108 
 6
antibody, while incubation with CpOGA completely removed the modification (Fig. 2b). Likewise, a time-109 
dependent increase in TAB1S395C GlcNAcylation was observed, indicating that S-GlcNAcylation represents 110 
a suitable structural mimic recognizable by the gTAB1 antibody (Fig. 2b). Gratifyingly, TAB1S395C S-111 
GlcNAcylation was resistant to CpOGA treatment. 112 
   To investigate whether protein S-GlcNAc transferase activity of OGT could occur in a different substrate 113 
sequence context, we generated a recombinant OGT linear fusion with a peptide derived from CK2 using a 114 
previously described approach28, in which the O-GlcNAcylation site was mutated to a Cys. In absence of a 115 
site-specific antibody for CK2 O-GlcNAc site (Ser347), we used the pan-specific O-GlcNAc antibody 116 
CTD110.6, which recognized both O-GlcNAcylated and S-GlcNAcylated CK2 fusion proteins (Extended 117 
Data Fig. 2). The latter was resistant against CpOGA hydrolysis, confirming our previous findings. Notably, 118 
S-GlcNAcylated TAB1 was also detectable with CTD110.6 (Extended Data Fig. 3), suggesting that this 119 
widely used antibody may be used as a tool to detect S-GlcNAcylation. These results are not entirely 120 
surprising, since CTD110.6 can cross-react with N-glycans and GlcNAcylated O-mannose, as well as 121 
terminal β-GlcNAc on complex N-glycans of cell surface glycoproteins29–31. On the other hand, another pan-122 
specific O-GlcNAc antibody RL2 does not suffer from such poor specificity towards the linkage type32 and 123 
reacted exclusively with O-GlcNAcylated TAB1 (Extended Data Fig. 3). 124 
   The crucial advantage of the OGT-assisted S-GlcNAcylation mimicry of protein O-GlcNAcylation is the 125 
ability to encode it genetically in living systems by engineering targeted, single Ser or Thr to Cys mutations. 126 
Having shown the application of our approach in vitro, we next investigated whether this could be extended 127 
to cultured mammalian cells. FLAG-tagged wild type and Ser395Cys TAB1 were expressed in IL-1R 128 
Hek293 cells27 that were optionally treated with GlcNAcstatin G33 to inhibit intracellular OGA. Additionally, 129 
lysates were treated with CpOGA to remove O-GlcNAc. As expected, O-GlcNAc-modified wild type TAB1 130 
was detected, with the modification being sensitive to CpOGA treatment (Fig. 2c).  Strikingly, we also 131 
detected GlcNAc modification on the Ser395Cys mutant, which was resistant to CpOGA hydrolysis (Fig. 132 
2c). In a separate experiment, treatment of cells overexpressing WT or S395C TAB1 with 4Ac5S-GlcNAc34, 133 
a metabolic precursor of the OGT inhibitor UDP-5S-GlcNAc, in both cases resulted in a disappearance of 134 
signal detected by the gTAB1 antibody, suggesting that in cells the S-GlcNAc modification is enzymatic 135 
(Extended Data Fig. 4). 136 
 137 
 138 
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Genetically directed S-GlcNAcylation allows dissection of O-GlcNAc function on OGA 139 
   Finally, we aimed to extend this approach to investigate the role of a single O-GlcNAc site on O-140 
GlcNAcase in cell culture. We pursued this goal by introducing the OGA Ser405Cys mutation in mouse 141 
embryonic stem cells (mESCs) with CRISPR-Cas9. Potential knock-in mutants were screened and several 142 
mutant lines were verified by sequencing (Supplementary Fig. 1-4). Due to the absence of a site-specific O-143 
GlcNAc OGA antibody as well as a lack of a proven immunoprecipitation-grade OGA antibody, we set out 144 
to quantify the stoichiometry of the GlcNAc modification on OGA in cell lysates, by performing GalTY289L 145 
labelling with GalNAz followed by click-chemistry reaction with an alkyne-labelled PEG 5000 to allow 146 
separation of glycosylated and unmodified OGA by SDS-PAGE16. Although the galactosyltransferase 147 
mutant GalTY289L is expected to label terminal GlcNAc residues, irrespective of the linkage type35, this 148 
approach has been mostly used for O-GlcNAc and terminal N-GlcNAc16,36. To validate this method for S-149 
GlcNAc, we first performed OGT reactions with WT and S395C recombinant TAB1, followed by a reaction 150 
with GalTY289L and subsequent PEGylation. Since the site-specific O-GlcNAc TAB1 antibody appears to 151 
recognize both O- and S-GlcNAcylated TAB1 with similar sensitivity, we used it as a control to monitor the 152 
successful OGT in vitro reaction as well as galactosyltransferase labelling efficiency based on the 153 
disappearance of GlcNAc signal detected by a gTAB1 antibody (Extended Data Fig. 5). Western blot 154 
analysis revealed complete labelling of S-GlcNAcylated TAB1, and comparable GlcNAcylation 155 
stoichiometry, indicating similar efficiency of both O- and S-GlcNAc transferase activities of OGT (Extended 156 
Data Fig. 5). Encouraged by these results, we applied this GlcNAc mass-tagging approach to OGA in 157 
mESC lysates. Quantification of GlcNAcylation stoichiometry revealed a rather low O-GlcNAcylation of 158 
OGA at a basal level (consistent with previously published data15,16), while the S405C mutation resulted in a 159 
GlcNAcylation stoichiometry of approximately 70%, similar to that induced by GlcNAcstatin G treatment on 160 
the wild type protein (Fig. 3a). It must be noted that due to the enzymatic nature of GalT labelling, the 161 
stoichiometry measured using this approach may be underestimated. Hyper-GlcNAcylation did not 162 
significantly affect OGA and OGT levels, while the O-GlcNAcase activity was preserved (Fig. 3b and 163 
Extended Data Fig. 6). Recent evidence has emerged suggesting that O-GlcNAcylation may directly affect 164 
protein stability37–39. This prompted us to investigate whether modification of OGA with GlcNAc could have 165 
an effect on its stability by monitoring the protein half-life (Fig. 3c). Interestingly, in a cycloheximide assay 166 
hyper-GlcNAcylated OGAS405C mutant had a significantly reduced half-life (approximately 6 h) compared to 167 
wild type OGA (approximately 20 h). To investigate whether this was through a direct effect on OGA 168 
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stability, we performed a cell lysate thermal shift assay that revealed no significant differences between wild 169 
type and S405C mutant OGA (Extended Data Fig. 7). Due to the fact that at basal conditions, OGA protein 170 
level appears to be unchanged, we speculate that owing to a compensation mechanism to maintain O-171 
GlcNAc homeostasis, OGAS405C may be synthesized at a faster rate to compensate for accelerated 172 
degradation of a permanently S-GlcNAcylated protein.  This suggests the presence of additional factors that 173 
affect OGA stability in a GlcNAcylation dependent mechanism.  174 
 175 
Discussion 176 
 In summary, we describe a simple and effective method for the rapid site-specific incorporation of a stable 177 
O-GlcNAc analogue in vitro and in cells by harnessing the unexpected cysteine S-GlcNAc transferase 178 
activity of OGT in combination with genome editing methods. We demonstrated that S-GlcNAc is a bona 179 
fide O-GlcNAc mimic by determining the crystal structure of a synthetic S-GlcNAcylated hOGA-derived 180 
peptide in complex with a model O-GlcNAc “reader” protein. We also showed that, despite micromolar 181 
affinity, S-GlcNAcylation is stable against OGA hydrolysis in the context of the hOGA- and α-synuclein-182 
derived peptides. By mutating the corresponding O-GlcNAc site to a cysteine, we validated the OGT-183 
mediated S-GlcNAcylation approach on TAB1 and CK2 in vitro and for the former – in cells. Utilizing 184 
CRISPR-Cas9 technology, we then directed OGT activity to the single specific site on OGA via genetic 185 
encoding of a S405C mutation in mESCs and demonstrated quantitative S-GlcNAcylation of OGA, while 186 
preserving its hydrolase activity. Intriguingly, this technique allowed us to provide the first insights into the 187 
importance of O-GlcNAc removal from Ser405 of OGA for the maintenance of its stability, suggesting the 188 
presence of a feedback regulation mechanism through as yet unknown additional factors. We anticipate 189 
that site-specific incorporation of S-GlcNAc would be useful for studying O-GlcNAc modifications that 190 
possess low stoichiometry due to the particularly rapid OGA-mediated hydrolysis. The S-GlcNAc genetic 191 
recoding method is likely applicable to proteins with multiple O-GlcNAc sites. By sequential mutagenesis of 192 
these sites to cysteines, it will be possible to dissect the roles of individual modifications. The added 193 
advantage of this method in vitro, is the ability to remove the hydrolysis-prone O-GlcNAc modifications 194 
through the action of OGA (CpOGA), leaving only S-GlcNAc modification on sites of interest intact. In 195 
addition, we show that some of the detection tools available for O-GlcNAc modification (such as O-GlcNAc-196 
specific antibodies and galactosyltransferase labelling) can also be applied to S-GlcNAc. The key 197 
advantage of our approach in cell studies is direct targeting of the residue of interest (a single atom 198 
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substitution in case of Ser to Cys mutation) without the need to express any artificial enzymatic machinery 199 
or treat cells with chemical compounds. Cys mutagenesis can be easily performed by common molecular 200 
biology techniques to study the modification in vitro and in an overexpression system.  Moreover, 201 
application of CRISPR-Cas9 gene editing technology now allows functional dissection of individual O-202 
GlcNAc sites on endogenous proteins in cells as well as model animals.  203 
 204 
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Figure 1: S-GlcNAc mimics O-GlcNAc in the context of an OGA peptide 318 
(a) Schematic representation of the human OGA sequence (including the O-GlcNAcylation site 319 
Ser405) and sequence conservation of Ser405 in vertebrates. GH domain – glycoside hydrolase 320 
domain. HAT-like domain – histone acetyltransferase-like domain. 321 
(b) MALDI-TOF mass spectra of synthetic O-/S-GlcNAc-modified peptides derived from hOGA with or 322 
without CpOGA treatment for 4 and 24 h. Loss of GlcNAc residue is characterized by the reduction 323 
in m/z by 203 Da. M – m/z, [M + Na] – m/z with a sodium adduct (23 Da), m/z – mass/charge ratio. 324 
(c) Fluorescence polarization assay dose-response curves showing the displacement of a fixed 325 
concentration of fluorescent probe (15 nM GlcNAcstatin B-FITC) from CpOGAD298N by increasing 326 
concentrations of O- or S-GlcNAcylated peptides derived from hOGA. Highest amount of probe 327 
bound to CpOGAD298N in the absence of competing O- or S-GlcNAcylated peptides was arbitrarily 328 
set as 100%. Data points were fitted to a four-parameter equation for dose-dependent inhibition 329 
using Prism (GraphPad). Data are shown as mean ± s.e.m. of n = 3 (O-GlcNAc peptide) and n = 4 330 
(S-GlcNAc peptide) independent experiments. KD values were calculated as described previously23. 331 
(d) Previously published O-GlcNAcylated hOGA-derived peptide (depicted as green sticks) in complex 332 
with CpOGAD298N (PDB: 2YDQ) and a crystal structure of S-GlcNAcylated hOGA-derived peptide 333 
(purple sticks) in complex with CpOGAD298N (deposited in the PDB as 6RHE). The unbiased |Fo-Fc| 334 
map before inclusion of any S-GlcNAc peptide model is shown as a blue mesh contoured at 2.5σ.  335 
CpOGAD298N active site residues are shown as grey sticks. Hydrogen bonds are shown as dashed 336 
lines. 337 
Source data for panel c are available with the paper online. 338 
  339 
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 340 
Figure 2: OGT catalyzes S-GlcNAcylation of TAB1S395C in vitro and in cells  341 
(a) LC-MS/MS EthCD S-GlcNAc site mapping on S395C TAB1 mutant. In vitro S-GlcNAcylated S395C 342 
TAB1 mutant (7-409) was digested with trypsin and subjected to LC–MS. The tryptic peptide 343 
VYPVSVPYCSAQSTSK (Mwcalc = 1918 Da) containing a HexNAc (+203.1 Da) was detected. The 344 
observed fragment ions (z, y, c and b ion series) are indicated in the fragmentation diagram. Mass 345 
differences between y7 to y8 and c8 to c9 allow confirmation of C395 as the site of S-GlcNAc 346 
modification. The c82+ ion corresponds to m/z 461.75528. 347 
(b) Time-course of TAB1WT and TAB1S395C in vitro OGT reaction. After 12 h incubation of TAB1WT and 348 
TAB1S395C with OGT, the reactions were treated with CpOGA. O- and S-GlcNAc modifications were 349 
detected by Western blot using an anti O-GlcNAc TAB1 (gTAB1) antibody.  350 
(c) OGT catalyzes S-GlcNAcylation of TAB1S395C in cells. IL-1R Hek293 cells were transfected with N-351 
terminally FLAG-tagged TAB1 constructs that were wild type or carried S395C or S395A mutations 352 
of the O-GlcNAc modification site. The cells were treated with OGA inhibitor GlcNAcstatin G (GG) 353 
for to elevate O-GlcNAc levels. The lysate was then split in half and one half was treated with 354 
CpOGA to remove O-GlcNAc (as monitored by Western blot using an anti-O-GlcNAc antibody RL2). 355 
Overexpressed TAB1 levels were assessed with an anti-FLAG antibody. Glycosylation levels of 356 
TAB1 were monitored with a site-specific O-GlcNAc TAB1 antibody (gTAB1). Tubulin was used as a 357 
loading control. Normalization was performed by dividing the gTAB1 antibody signal (O-GlcNAc 358 
TAB1) by the FLAG signal (total TAB1). “*” denotes P = 0.0377, “***” denotes P = 0.0001, calculated 359 
by Student’s t-test (two-tailed, unpaired) Data are shown as mean ± s.e.m. of n = 3 biological 360 
replicates. Uncropped Western blot images and source data for panel 2c are available with the 361 
paper online. 362 
  363 
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Figure 3: OGT catalyzes hydrolytically stable cysteine-S-GlcNAcylation of OGA in cells, which 364 
reduces OGA stability 365 
(a) Quantification of O- and S-GlcNAcylation stoichiometry on OGA was performed by chemoenzymatic 366 
labelling with GalNAz using a galactosyltransferase Y289L mutant (GalT) and subsequent click-367 
chemistry reaction with a 5 kDa PEG-alkyne. Labelling was performed on cell lysates from cells 368 
expressing wild type OGA (cells were either untreated or treated with 1 ∝M GlcNAcstatin G (GG) as 369 
a positive control) and OGAS405C mutant. Reactions were assessed by Western blot using an anti-370 
OGA antibody. Upward molecular weight shift corresponds to GlcNAc modified OGA (gOGA). 371 
Plotted are the GlcNAcylation stoichiometries of wild type (undetectable) and S405C mutant OGA. 372 
Data are shown as mean ± s.e.m. of n = 3 biological replicates. 373 
(b) Quantification of OGA and total O-GlcNAc levels in wild type OGA and OGAS405C mutant mES cells 374 
by Western blot analysis. α-tubulin was used as a loading control. Data are shown as mean ± s.e.m. 375 
of n = 6 (WT OGA) and n = 9 (OGAS405C) biological replicates.  NS – no significant difference 376 
(analyzed by two-tailed Student’s t-test). 377 
(c) OGA stability was measured by treating cells with cycloheximide at a final concentration of 20 μg/ml 378 
and harvesting cells at indicated time points for Western blot analysis using an anti-OGA antibody. 379 
Normalization of band intensities was performed by dividing OGA signal by α-tubulin signal.  380 
Untreated normalized sample was assigned as 100% OGA. “*” denotes P = 0.0399, “**” denotes P = 381 
0.00115, calculated by Student’s t-test (two-tailed, unpaired). Data are shown as mean ± s.e.m. of n 382 
= 6 biological replicates (using three independent replicates for clones 27, 36 and two independent 383 
replicates for clones 37, 39, 74). CHX – cycloheximide. Uncropped Western blot images and source 384 
data for panels a-c are available with the paper online. 385 
  386 
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Table 1. Data collection and refinement statistics.  387 
 
 388 
The dataset was collected from a single crystal. aValues in parentheses are for highest-resolution shell. 389 
  
 CpOGA–hOGA (S-GlcNAc) peptide 
(PDB 6RHE) 
Data collection  
Space group P61 
Cell dimensions  
    a, b, c (Å) 117.7, 117.7, 147.9 
    α, β, γ  (°)  90º, 90º, 120º
Resolution (Å) 48.17 - 3.1 (3.21 - 3.1)a 
Rmerge 0.1077 (1.123) 
I / σI 
CC1/2 
9.13 (1.10) 
0.994 (0.379) 
Completeness (%) 93.85 (95.67) 
Redundancy 3.2 (3.3) 
 
 
 
Refinement  
Resolution (Å) 48.17-3.1 
No. reflections 19790 (1990) 
Rwork / Rfree 0.1949/0.2270 
No. atoms  
    Protein 4594 
    S-GlcNAc peptide 
    Cadmium ion 
43 
25 
    Water 28 
B-factors  
    Protein 84.34 
    S-GlcNAc peptide 
    Cadmium 
112.10 
138.30 
    Water 69.83 
R.m.s. deviations  
    Bond lengths (Å) 0.013 
    Bond angles (°) 1.61 
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Materials & Methods 390 
 391 
Glycopeptide synthesis 392 
Peptides VAHS(O-GlcNAc)GA, VAHC(S-GlcNAc)GA, GAVVT(O-GlcNAc)GVTA and GAVVC(S-393 
GlcNAc)GVTA were synthesized as described previously25, using 3,4,6-triacetyl-O-GlcNAc-Fmoc-Ser-OH 394 
and 3,4,6-triacetyl-S-GlcNAc-Fmoc-Cys-OH as building blocks.  395 
 396 
Synthesis of Cys-S-GlcNAc building block 397 
Details of instrumentation and analytical procedures were reported elsewhere40. Fmoc-GlcNAc-S-Cys-OAll 398 
was prepared from Boc-GlcNAc-S-Cys-OAll41.  399 
 400 
To a stirred solution of 1 (1.98 g, 3.35 mmol) in trifluoroethanol (TFE; 20 mL) concentrated HCl (1.5 mL) 401 
was added at RT. The reaction mixture was further stirred for 45 min; tlc [PE–DCM]–Me2CO 30% showed 402 
complete consumption of the starting material and formation of a more polar product. The reaction was 403 
diluted with CHCl3 and toluene, concentrated, and briefly dried in vacuum. The residue was dissolved in 404 
1,4-dioxan-water 3:1 mixture (40 mL) and treated sequentially with solid NaHCO3 (0.76 g, 9 mmol) and 405 
FmocCl (1 g, 4 mmol). The clear solution with some solid deposit was stirred at RT for 1 h; tlc 406 
[PE˗DCM]˗Me2CO 40% showed formation of a less polar new product. The residue was purified by flash-407 
column chromatography [PE−DCM 4:1]−Me2CO 10→40% to give 2.35 g (3.33 mmol, quant) of the target 408 
product as amorphous solid.  409 
1H NMR (500 MHz, DMSO-d6) δ 7.94 (d, J = 9.4 Hz, 1H), 7.90 (d, J = 7.6 Hz, 2H), 7.75 (d, J = 8.1 Hz, 1H), 410 
7.72 (d, J = 7.5 Hz, 2H), 7.43 (t, J = 7.4 Hz, 2H), 7.37 – 7.31 (m, 2H), 5.91 (ddt, J = 17.2, 10.5, 5.2 Hz, 1H), 411 
5.34 (dq, J = 17.3, 1.7 Hz, 1H), 5.21 (dq, J = 10.5, 1.6 Hz, 1H), 5.10 (t, J = 9.8 Hz, 1H), 4.88 (t, J = 9.7 Hz, 412 
1H), 4.78 (d, J = 10.4 Hz, 1H), 4.61 (dt, J = 5.1, 1.6 Hz, 2H), 4.38 (td, J = 8.8, 4.9 Hz, 1H), 4.35 – 4.28 (m, 413 
2H), 4.25 (t, J = 6.9 Hz, 1H), 4.14 (dd, J = 12.3, 5.1 Hz, 1H), 4.03 (dd, J = 12.2, 2.4 Hz, 1H), 3.92 (q, J = 414 
10.3 Hz, 1H), 3.86 (ddd, J = 10.1, 5.0, 2.5 Hz, 1H), 3.15 (dd, J = 13.8, 4.8 Hz, 1H), 2.85 (dd, J = 13.8, 9.4 415 
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Hz, 1H), 1.99 (s, 3H), 1.99 (s, 3H), 1.93 (s, 3H), 1.76 (s, 3H) (Supplementary Fig. 5). m/z (ESI-TOF) found: 416 
713.2344 expected for C35H40N2O12S (M+H+), 713.2380  417 
 418 
To a cold (ice-bath) solution of 2 (0.355 g, 0.5 mmol) in THF (2.5 mL, 0.2 M) phenyl silane (PhSiH3; 0.092 419 
mL, 0.75 mmol) was added followed by tetrakistriphenylphosphine palladium (Pd(PPh3)4; 0.007 g, 0.00625 420 
mmol). The reaction was removed from the cooling bath and stirred for 20 min; tlc [PE‒DCM 4:1]‒EA 30% 421 
revealed the reaction was complete. The reaction was concentrated. The crude acid 3 was dried in vacuum 422 
and used in the peptide synthesis without purification. 423 
 424 
Analysis of O- and S-GlcNAc hydrolysis 425 
hOGA- and α-synuclein-derived O- and S-GlcNAc peptides were diluted to 0.5 mM in 50 μl TBS buffer. To 426 
initiate the reaction, CpOGA was added to a final concentration of 0.3 μM. Hydrolysis reactions were 427 
performed at 37 °C for 4 or 24 h. Samples not treated with CpOGA were used as negative controls. To 428 
separate the peptides from CpOGA, all samples were passed through a 10 kDa molecular weight cut-off 429 
spin column. For MALDI-TOF MS analysis, samples were diluted in 0.1% TFA and 2 pmol was used for 430 
loading. 2,5 dihydroxy benzoic acid was used as a matrix. The samples were run in a rapifleX MALDI-TOF 431 
MS system. 432 
 433 
Fluorescence polarization assay 434 
Experiments were performed in black 384-well plates as described previously23. Reaction mixtures 435 
contained (added in order): O- or S-GlcNAc-modified peptide derived from hOGA (VAHS/C(GlcNAc)GA) or 436 
α-synuclein (GAVVT/C(GlcNAc)GVTA) at varying concentrations, 16 nM CpOGAD298N inactive mutant and 437 
5 nM fluorescent probe (GlcNAcstatin-B-FITC) in TBS buffer pH 7.5 containing 1% DMSO. Fluorescence 438 
polarization (in millipolarization units) was measured using a Pherastar FS plate reader at excitation and 439 
emission wavelengths of 485 nm and 530 nm, respectively. Background subtraction was performed using 440 
reactions that did not contain CpOGAD298N and data were fitted with GraphPad Prism as described 441 
O
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previously23. Assays using O-GlcNAcylated peptides were performed with three technical replicates in three 442 
independent experiments. Assays using S-GlcNAcylated peptides were performed with a single technical 443 
replicate in three (α-synuclein peptide) or four (hOGA peptide) independent experiments. 444 
 445 
Crystallography 446 
CpOGAD298N  was purified and crystallized as previously described25. Soaking with S-modified peptide was 447 
performed by transferring crystals into a 0.5 μl drop of fresh crystallization buffer containing 10 mM of the 448 
peptide for 4 h at 20 °C. The crystals were mounted in nylon loops, cryo-protected in 0.175 M CdSO4, 0.6 M 449 
NaAc buffer containing 20% glycerol and flash-frozen in liquid nitrogen prior to data collection. Diffraction 450 
datasets were collected at the ID29 beam line (wavelength 0.9686 Å) of the European Synchrotron 451 
Radiation Facility (ESRF, Grenoble, France). Datasets were indexed and integrated with XDS42 and further 452 
reduced and scaled with Aimless. The CpOGA structure in complex with an S-GlcNAc hOGA peptide was 453 
solved by molecular replacement using published CpOGA-(O-GlcNAc hOGA peptide) complex structure 454 
(PDB: 2YDQ25)  without the ligand as a phase donor in MOLREP43. The resulting model was submitted to 455 
several cycles of refinement with REFMAC544 followed by manual modelling with COOT45. Statistics of the 456 
data collection and model refinement are summarized in Table 1. The Ramachandran statistics are as 457 
follows: 96.55% favored, 3.45% additionally allowed. Figures of the structures were generated with Pymol46. 458 
 459 
Cloning 460 
The gene coding for full length TAB1 was cloned as a BamHI-NotI fragment into the pCMV-FLAG vector 461 
(obtained from DSTT, School of Life Sciences, Dundee, UK) for expression of N-terminal FLAG tag. The 462 
products were gel extracted and digested with BamHI and NotI restriction enzyme. The products were gel 463 
extracted and digested before being ligated into pCMV-FLAG cut with BamHI and NotI. The inserts were 464 
confirmed by DNA sequencing. Wild type pGEX6P1 TAB1 7-409 construct was produced as described 465 
previously28. The S395C mutation was introduced by site-directed mutagenesis based on the QuikChange 466 
protocol by Stratagene but using KOD Polymerase. All inserts were confirmed by DNA sequencing. Primers 467 
used for cloning and sequencing are listed in Supplementary Table 1. 468 
 469 
 470 
 471 
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In vitro OGT reactions and OGT-CK2 linear fusion 472 
In vitro OGT reaction (100 μl) contained 10 μM TAB1 (7-409 construct), 50 nM full length human OGT in 473 
TBS buffer pH 7.5 with 0.1 mg/ml bovine serum albumin (BSA). The reaction was initiated by addition of 474 
UDP-GlcNAc to a final concentration of 100 μM. Reactions were performed at 25 °C. After incubation with 475 
OGT, the reactions were treated with 3 μM CpOGA for 2 h at 37 °C. 5 μl of the reaction was taken at 476 
different time points, run on the SDS PAGE gel and analyzed by Western blotting using O-GlcNAc TAB1 477 
and total TAB1 antibodies. The OGT-CK2 peptide linear fusion was produced as described previously28. 478 
 479 
Mass spectrometry 480 
TAB1S395C OGT in vitro reaction was run on SDS-PAGE, the corresponding TAB1 band was excised and 481 
processed by in-gel digestion. The gel slice was washed with water, shrunk with 100 μl of acetonitrile (ACN) 482 
for 5 min at room temperature and reswollen with 50 μl of 50 mM Tris HCl pH 8.0 twice. Reduction and 483 
alkylation were performed in gel using 50 μl of 5 mM DTT in 50 mM Tris HCl pH 8.0 (shaken for 20 min at 484 
65 °C) and 50 μl of 50 mM iodoacetamide in 50 mM Tris HCl pH 8.0 (shaken for 20 min at room 485 
temperature). The gel slice was shrunk using 500 μl ACN for 5 min at room temperature and 50 μl of 50 486 
mM triethylammonium bicarbonate was added to reswell the gel slice. 50-100 μl of mass spectrometry 487 
grade trypsin in 50 mM triethylammonium bicarbonate, containing 5 μg/ml of trypsin protease (in 50 mM 488 
acetic acid) was added and the sample was shaken at 30 °C overnight. 100 μl of ACN was added to 489 
completely shrink the gel. The supernatant was transferred to a fresh tube. The gel piece was re-swollen 490 
with 50 μl of 0.1% trifluoroacetic acid (TFA). Digest was extracted twice with 100 μl of ACN. All extracts 491 
were combined, lyophilized in a speed-vac and stored at -20 °C. Mass spectrometric analysis was 492 
performed by LC-MS/MS on an Orbitrap Fusion tribrid mass spectrometer (Thermo Scientific) coupled to a 493 
U3000 RSLC HPLC (Thermo Scientific). Peptides were trapped on a nanoViper Trap column, 2 cm x 100 494 
μm, C18 5 μm 100 Å (Thermo Scientific, 164564) and then separated on a 50 cm EASY-Spray column 495 
(Thermo Scientific, ES803) equilibrated with a flow of 300 nl/min of 3% Solvent B (Solvent A: 2% 496 
Acetonitrile, 0.1% formic acid; Solvent B: 80% acetonitrile, 0.08% formic acid). The elution gradient was as 497 
follows: time (min): solvent B (%); 0:3, 5:3, 55:25, 74:40, 79:99, 80:3, 90:3. The instrument was operated 498 
with the internal mass calibrant (EASY IC) option to improve the mass accuracy of precursor ions and data 499 
were acquired in the data-dependent mode.  MS1 spectra (m/z 400-1600) were acquired in the Orbitrap 500 
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with resolution 120,000. The method used was a ‘top speed’ method. The precursors were isolated using 501 
quadrupole with an isolation width of 1.6 Da. The activation type was HCD (Higher-energy Collisional 502 
Dissociation) with collision energy at 30% and the fragments were detected in ion trap mass analyzer. The 503 
AGC (Automatic Gain Control) target set was 100 and the maximum injection time was set at 250 ms. If an 504 
ion in this analysis shows the presence of certain ions, in this case any of HexNAc (204.1), HexNAc 505 
fragment (138.1) or HexNAcHex (366.1) then EThcD/Orbitrap analysis of the parent ion was triggered. The 506 
ions were isolated using quadrupole and fragmentation method used was ETD (Electron Transfer 507 
Dissociation) with HCD supplemental activation (EThcD). The Orbitrap resolution for this step was set at 508 
30000. The AGC target was 30000 and the maximum injection time was 150 ms. Data files were analyzed 509 
by Proteome Discoverer 2.0 (Thermo Scientific), using Mascot 2.4.1 (www.matrixscience.com), and 510 
searching an in-house database containing the relevant sequences. Scaffold 511 
(www.ProteomeSoftware.com) was also used to examine the Mascot result files. Allowance was made for 512 
the following variable modifications Oxidation (M), HexNAc (S), HexNAc (C). Error tolerances were 10 ppm 513 
for MS1, 0.6 Da for HCD MS2 and 20 mmu for EThcD/Orbitrap spectra 514 
 515 
Cell culture and transfection 516 
IL-1R Hek293 cells27 were grown in DMEM medium supplemented with 10% FBS, 2 mM L-glutamine and 517 
1% penicillin/streptomycin (100 U/ml and 100 μg/ml respectively) at 37 °C and 5% CO2. Hek293 cells were 518 
transfected with FLAG-tagged TAB1 using Lipofectamine 3000 reagent (Invitrogen) at a ratio 1:2 (μg:μl) 519 
according to manufacturer’s instructions. Male mouse embryonic stem cells (AW2 line from MRC Centre for 520 
Regenerative Medicine, Institute for Stem Cell Research, University of Edinburgh) were cultured in 0.1% 521 
(w/v) gelatin-coated plates in GMEM BHK-21 medium supplemented with 10% fetal bovine serum, 50 μM 522 
β−mercaptoethanol, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate and 100 U/ml leukemia 523 
inhibitory factor at 37 °C and 5% CO2. Cell lines tested negative for mycoplasma. GlcNAcstatin G treatment 524 
was performed at a final concentration of 1 μM for 24 h. 4Ac5S-GlcNAc treatment was performed at a final 525 
concentration of 200 μM for 24 h.  526 
 527 
 528 
 529 
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Generation of OGA S405C CRISPR-Cas9 knock-in mouse embryonic stem cells 530 
Paired gRNAs were selected using the website http://www.sanger.ac.uk/htgt/wge/find_crisprs. Annealing 531 
oligonucleotides were designed with the appropriate overhangs for cloning into BpiI cut pX335 (Cas9 D10A) 532 
and pBABED puro U6. A 3 μM mix of each annealing oligonucleotide pair were combined in a 100 μl 533 
volume and treated with 1 μl polynucleotide kinase (Fermentas) in T4 Ligase buffer at 37 °C for 20 min 534 
followed by 10 min incubation at 75 °C and finally placed in a heating block at 95 °C. The metal block was 535 
removed from the heat source and allowed to cool gradually to room temperature. 1 μl of a 1/30 dilution of 536 
this mixture was added to a ligation reaction containing 20 ng BpiI cut, dephosphorylated destination vector 537 
and 1 μl DNA ligase (Fermentas) in T4 ligase buffer in a 20 μl final volume. After 25 min at RT a 1 μl aliquot 538 
of the reaction was used to transform DH5-alpha competent cells. Inserts were confirmed by DNA 539 
sequencing. A 2 kb PCR product was obtained from 46c mouse genomic DNA and cloned as a BamHI-NotI 540 
fragment into pGEX6P1. The insert was confirmed to be wild type by DNA sequencing. A 249 bp geneblock 541 
containing the desired mutation and silent mutations to eliminate the gRNA recognition sites was ordered 542 
from Integrated DNA Technologies. The geneblock was amplified by PCR, the product was gel extracted 543 
and introduced into the middle of the 2 kb insert by restrictionless cloning47. The changes were confirmed 544 
by DNA sequencing. 545 
Male mouse embryonic stem cells were co-transfected with pBABED, pX335 and the repair template 546 
plasmids using Lipofectamine 3000 (Invitrogen) according to manufacturer’s instructions. 24 h post 547 
transfection, G-MEM medium (supplemented with 10% fetal bovine serum, β-mercapthoethanol, non-548 
essential amino acids, sodium pyruvate and leukemia inhibitory factor) was substituted with fresh medium 549 
containing 1 μg/ml puromycin. Cells that survived after 24 h of puromycin treatment were dissociated with 550 
accutase, and plated onto several 10 cm plates. Colonies were grown for 1-2 weeks and then screened by 551 
restriction digestion of a 622 bp PCR product (covering the mutation site) with DraI enzyme. Wild type 552 
restriction digestion produced two 231 and 391 bp bands on a 1.3% agarose gel. The S405C mutant 553 
produced a single 622 bp band, which was verified by sequencing (Supplementary Fig. 1 and 2). To 554 
eliminate the possibility of a false positive due to random integration of the repair template into the genome 555 
and to detect the presence of hemizygous genomic deletions, a larger PCR product was obtained. This 556 
PCR product encompassed an area outside the repair template and sequencing confirmed the change in 557 
the correct location (Supplementary Fig. 3). This confirmed the desired homologous recombination had 558 
taken place.  Primers used for knock-in generation and sequencing are listed in Supplementary Table 1. 559 
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In addition to DNA based analysis of mutated cell lines, RNA was extracted from candidate clones 560 
containing the S405C mutation. This RNA was subjected to one-step RT-PCR (using Takara Primescript 561 
High Fidelity RT-PCR Kit) with primers specific to the next exon outside the area covered by the repair 562 
template in both directions. This resulted in a 951 bp PCR product. Sequencing of the resultant product 563 
from both ends confirmed the precision of the alteration of the mRNA expressed in these cells 564 
(Supplementary Fig. 4). Primers and geneblock sequence are listed in Supplementary Table 1. 565 
 566 
Western blotting 567 
Cells were scraped in lysis buffer (Cell Signaling Technology, #9803) supplemented with 1 mM PMSF, 568 
sonicated and lysates were spun down at 17000 g for 10 min. Supernatants were transferred into fresh 569 
tubes and protein concentration was quantified using Bradford assay. Protein samples were prepared using 570 
LDS buffer containing 5% β-mercaptoethanol. Samples were run on a 10% SDS PAGE gel. Proteins were 571 
then transferred onto nitrocellulose membrane at 100 V for 1 h. Membranes were stained with Ponceau-S 572 
to check for successful transfer, washed with 0.2% TBS-Tween and blocked in 5% BSA in 0.2% TBS-573 
Tween. Primary antibodies are listed in Supplementary Table 2. Fluorescence signal from secondary 574 
antibodies (Li-Cor) was quantified using Image Studio software and statistical analysis was performed using 575 
Prism (GraphPad). 576 
 577 
O- and S-GlcNAc PEGylation labelling using Gal-TY289L 578 
The Click-iTTM O-GlcNAc enzymatic labelling system was used according to manufacturer’s instructions 579 
(Thermo Fisher Scientific) with some modifications. 50-100 μg of whole cell lysate proteins or 20 μg of in 580 
vitro GlcNAcylated TAB1 were subjected to Gal-TY289L labelling. The Gal-TY289L reaction components were 581 
added in the following order to 20 μl of chloroform/methanol precipitated proteins (in 20 mM HEPES, pH 582 
7.9): 24.5 μl MiliQ water, 40 μl labelling buffer (component C), 5.5 μl MnCl2 (100 mM, component D) and 583 
vortexed briefly. 10 μl 0.5 mM UDP-GalNAz was added, mixed by pipetting and half of the reaction (50 μl) 584 
was removed as an unlabeled negative control. Finally, 4 μl Gal-TY289L was added to the reaction and 585 
mixed by pipetting. Both the reaction and the negative control were incubated at 4 °C overnight. 586 
PEGylation of GalNAz-labelled proteins was performed using the Click-iT® Protein Reaction Buffer Kit 587 
according to manufacturer’s instructions (Thermo Fisher Scientific) with some modifications. MeO-PEG-588 
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alkyne (Mw = 5000 Da, IrisBiotech, PEG2830.0500) was prepared beforehand as a 10 mM solution in water 589 
and stored at -20 °C. Proteins (20 μl in 1% SDS, 50 mM Tris HCl, pH 8.0) prepared by GalNAz labelling 590 
were mixed with 40 μl Click-iT ® reaction buffer containing 3.3 mM PEG-alkyne (i.e. 100 μl of PEG-alkyne 591 
stock solution was mixed with 200 μl of Click-iT® reaction buffer, component A). 4 μl of CuSO4 was added, 592 
followed by 8 μl of Click-iT® reaction buffer additive 2 solution. The reaction was then incubated at room 593 
temperature with 1400 rpm shaking for 1-1.5 h. The samples were prepared in LDS buffer (containing 5% 594 
β-mercaptoethanol) and analyzed by Western blotting. 595 
Cycloheximide treatment 596 
mES cells were treated with cycloheximide (Cayman Chemical, dissolved in DMSO) at a final concentration 597 
of 20 μg/ml for different time points before lysis. DMSO treatment was used as a negative control.  598 
 599 
OGA thermal stability assay in cell lysates 600 
mES cells were lysed as described above and subjected to a range of temperatures in a thermomixer. After 601 
5 min of incubation at each temperature, the lysates were centrifuged and soluble fraction was removed for 602 
subsequent Western blot analysis.  603 
 604 
Reporting Summary  605 
Further information on experimental design is available in the Nature Research Reporting Summary linked 606 
to this article. 607 
 608 
Data Availability  609 
Atomic coordinates and structure factors for the CpOGA–(S-GlcNAc peptide) complex structure are 610 
deposited in the Protein Data Bank under the accession code PDB 6RHE. Source data for Fig. 1c, 2c, 3a, 611 
3b, 3c and Extended Data Fig. 1b, 6, 7 are available with the paper online. All other data are available upon 612 
reasonable request to the corresponding author.   613 
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